Apr. 1 at 2:25 PM
$PPBT what does @Stocktwits think about @PurpleBiotech acquiring dirt cheap
$SYRS for their pancreatic cancer asset from
$TYME a few years ago?
Their MDS asset failed but there still might be promise in SY-5609, which received an orphan drug designation (ODD) two years ago:
https://ir.syros.com/press-releases/detail/258/syros-receives-fda-orphan-drug-designation-for-sy-5609-for